Product Description
ANX1502 is an investigational oral small molecule inhibitor of the classical complement cascade designed for the treatment of autoimmune diseases. ANX1502 has the potential to be a game-changing first-in-class small molecule classical complement inhibitor for a broad and deep set of autoimmune conditions. (Sourced from: https://ir.annexonbio.com/news-releases/news-release-details/annexon-biosciences-highlights-portfolio-progress-and-key)
Mechanisms of Action: C1 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Annexon
Company Location: SOUTH SAN FRANCISCO CA 94080
Company CEO: Douglas Love
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Netherlands
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Autoimmune Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ANX1502-NHV-01 | P1 |
Completed |
Autoimmune Diseases |
2024-11-19 |